Michael Henderson, M.D., currently serves as the Chief Executive Officer at Apogee Therapeutics Inc., a biopharmaceutical company focused on developing transformative therapies for patients with high unmet medical needs. Dr. Henderson brings a wealth of experience in the biopharmaceutical industry, having held leadership positions at several prominent companies. Prior to joining Apogee, he served as the Chief Medical Officer at a leading biotechnology firm, where he played a pivotal role in advancing the company's clinical development programs and securing regulatory approvals for groundbreaking treatments. Throughout his career, Dr. Henderson has been recognized for his contributions to the field of medicine and his dedication to improving patient outcomes. He has authored numerous peer-reviewed publications and has been an invited speaker at various international conferences. His expertise spans multiple therapeutic areas, including oncology, immunology, and rare diseases. Under his leadership at Apogee Therapeutics, Dr. Henderson is spearheading the company's efforts to develop a robust pipeline of innovative therapies, leveraging cutting-edge science and technology to address some of the most challenging diseases. As CEO of Apogee Therapeutics, Dr. Henderson is responsible for setting the strategic direction of the company and overseeing its day-to-day operations. He works closely with the executive team and board of directors to ensure that Apogee remains at the forefront of biopharmaceutical innovation. His visionary leadership and commitment to excellence have positioned Apogee as a promising player in the industry, with the potential to make a significant impact on the lives of patients worldwide.